Altera Biosciences is a preclinical-stage biotechnology company developing a universal donor cell platform designed to enable scalable, immune-compatible, off-the-shelf allogeneic cell therapies. The platform leverages induced pluripotent stem cells (iPSCs) and gene regulation technologies to engineer cells that bypass donor-recipient matching and immunosuppressive regimens. This approach aims to address the challenge of immune compatibility in cell and tissue transplantation, particularly for genetically diverse populations.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and organ transplantation is often limited by immune compatibility, requiring patients to find immunologically matched donors—a process dependent on scarce donor availability, individualized preparation, and lifelong immunosuppression. These limitations result in delayed treatments, high costs, and restricted access, particularly in low-resource or time-sensitive settings, and are especially acute in Africa given its unmatched genetic diversity.
Solution
Altera Biosciences is developing a universal donor cell platform designed to enable scalable, immune-compatible, off-the-shelf allogeneic therapies for cell and tissue transplantation. The company leverages the unlimited self-renewing capabilities of induced pluripotent stem cells (iPSCs) and advanced gene regulation technologies to engineer cells that are immune-compatible across recipients. By removing the identity markers on donor cells that trigger immune rejection, the platform aims to bypass the need for donor matching or rejection-prone immunosuppressive regimens. This approach is intended to make cell therapy more scalable, accessible, and impactful across the globe, with the potential to expand access to safe, timely, and effective treatment options for diverse patient populations.
Target Audience
Primary customers are cell and gene therapy developers, pharmaceutical companies, and clinical researchers seeking scalable, immune-compatible cell sources for allogeneic therapies and transplantation medicine.
Features
- Universal donor cell platform engineered for immune compatibility across recipients, eliminating the need for donor-recipient matching
- Use of induced pluripotent stem cells (iPSCs) for unlimited self-renewing cell sources
- Gene silencing technology to remove identity markers on donor cells that trigger immune rejection
- Platform designed to support off-the-shelf, allogeneic cell therapies for scalable manufacturing and distribution
- Technology applicable beyond transplantation, with potential applications across multiple areas of medicine